NEW YORK (
) hit a new 52-week high Wednesday as it is currently trading at $14.80, above its previous 52-week high of $14.76 with 2.2 million shares traded as of 3:40 p.m. ET. Average volume has been 3.2 million shares over the past 30 days.
Ariad has a market cap of $2.24 billion and is part of the
industry. Shares are up 18.4% year to date as of the close of trading on Tuesday.
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Ariad as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full
52-week high stocks
or get investment ideas from our